Hanlim Pharm Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-03-14
- Employees
- 251
- Market Cap
- -
- Website
- http://hanlim.com
A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT03278470
- Locations
- 🇰🇷
The catholic university of korea seoul ST. mary's hospital, Soeul, Korea, Republic of
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: Sevikar tab. 10/40mgDrug: Lodivikar tab. 5/40mg
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02955498
- Locations
- 🇰🇷
Metrohospital, Anyang, Kyung Gi, Korea, Republic of
Repeated Dosing Clinical Trial of HL151
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02686294
- Locations
- 🇰🇷
The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of
Single Dosing Clinical Trial of HL151
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02682745
- Locations
- 🇰🇷
The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of
A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
Phase 2
Completed
- Conditions
- Acute Exacerbations of Chronic BronchitisAcute Bronchitis
- Interventions
- Drug: HL301 300mg capsuleDrug: Placebo
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT02250027
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca
Phase 1
Completed
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: Livasupril Cap.160/2mgDrug: Lipilfen cap. 160mgDrug: Livaro tab. 2mg
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT02250976
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT02229955
- Locations
- 🇰🇷
The catholic university of Korea seoul st. Mary's hospital, Seoul, Seocho-Ku, Korea, Republic of
To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
Phase 4
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: Risedronate/Cholecalciferol combination(montly)Drug: Risedronate/Cholecalciferol combination(weekly)
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT01904110
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: Lodivixx tab. 5/160mg
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT01819779
- Locations
- 🇰🇷
Metro Hospital, Anyang, Kyung Gi, Korea, Republic of
Post-menopausal Women Osteoporosis(Phase III)
Phase 3
Completed
- Conditions
- Postmenopausal Women Osteoporosis
- Interventions
- Drug: Placebo(for Risedronate)
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01806792
- Locations
- 🇰🇷
Chung-ang university hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath